不可手术切除的肝内胆管细胞癌局部治疗进展

肝癌电子杂志 ›› 2020, Vol. 7 ›› Issue (4): 44-47.

不可手术切除的肝内胆管细胞癌局部治疗进展

李书沛¹, 余晨曦¹, 来凤勇¹, 宋鹏¹, 杜春霞², 姚雪松^3,*

1 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院深圳医院介入治疗科,广东深圳 518116;
2 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院肿瘤内科,北京100021;
3 国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院介入治疗科,北京100021

收稿日期:2020-07-01 发布日期:2021-02-02
通讯作者: *姚雪松 E-mail: yaoxuesong2005@hotmail.com
作者简介:李书沛,主治医生,中国医学科学院北京协和医学院肿瘤医院,深圳医院,介入治疗科
基金资助:
国家自然科学基金面上项目（81671798）

Local therapy for unresectable intrahepatic cholangiocarcinoma

Li Shupei¹, Yu Chenxi¹, Lai Fengyong¹, Song Peng¹, Du Chunxia², Yao xuesong^3,*

1 Department of Interventional Therapy, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116,Guangdong,China;
2 Department of Medical Oncology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China;
3 Department of Interventional Therapy, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China

Received:2020-07-01 Published:2021-02-02

摘要/Abstract

摘要： 肝内胆管细胞癌是指起源于二级及其以上肝内胆管上皮细胞的恶性肿瘤,具有早期诊断困难、恶性程度高及预后差等特点。肝内胆管细胞癌较为少见,在原发性肝脏恶性肿瘤中,其发病率仅次于肝细胞癌,是肝脏第二大原发恶性肿瘤。近年来,肝内胆管细胞癌的发病率及死亡率有不断升高的趋势,手术切除是目前唯一的根治手段,但大部分患者确诊时已失去手术时机。随着局部治疗技术的不断进展,对于不可手术切除的肝内胆管细胞癌患者,局部治疗可以降低肿瘤负荷、缓解症状、延长生存期,甚至有机会通过局部治疗获得手术机会。目前常见的局部治疗手段主要包括：消融治疗、经血管途径治疗及放射治疗。本文对肝内胆管细胞癌目前主要局部治疗现状及进展进行综述,以期对肝内胆管细胞癌的综合治疗提供更多参考。

关键词: 肝内胆管细胞癌, 局部治疗, 消融, 经血管治疗, 放射治疗

Abstract: Intrahepatic cholangiocarcinoma refers to a malignant tumor that originates from the epithelial cells of the secondary bile duct and the branches of the intrahepatic bile duct. With the characteristics of difficult early diagnosis, high malignancy and poor prognosis. Although intrahepatic cholangiocarcinoma is relatively rare, it’s still the second most common primary malignant tumor of the liver following the hepatocellular carcinoma. In recent years, the morbidity and mortality of intrahepatic cholangiocarcinoma have been increasing. Surgical resection is currently the only radical cure, but most patients have lost the opportunity for surgery when they are diagnosed. With local treatment technology has made great progress. Those patients with unresectable intrahepatic cholangiocarcinoma, could get benefits from local treatment in terms of tumor burden reducing, symptoms relieved, prolong survival, and even transforming to surgery available. The current common local treatment methods mainly include: ablation treatment, transvascular treatment and radiotherapy. This article reviews the current status and progress of the main local treatments for intrahepatic cholangiocarcinoma. In order to get more approaches to multiple discipline therapy in intrahepatic cholangiocarcinoma.

Key words: Intrahepatic Cholangiocarcinoma, Local Therapy, Ablation, Transarterial Therapy, Radiation Therapy

李书沛, 余晨曦, 来凤勇, 宋鹏, 杜春霞, 姚雪松. 不可手术切除的肝内胆管细胞癌局部治疗进展[J]. 肝癌电子杂志, 2020, 7(4): 44-47.

Li Shupei, Yu Chenxi, Lai Fengyong, Song Peng, Du Chunxia, Yao xuesong. Local therapy for unresectable intrahepatic cholangiocarcinoma[J]. Electronic Journal of Liver Tumor, 2020, 7(4): 44-47.

参考文献

[1] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019 年版)[J]. 肝癌电子杂志,2020, 7(1):5-23.
[2] BLECHACZ B,KOMUTA M,ROSKAMS T,et al.Clinical diagnosis and staging of cholangiocarcinoma[J].Nat Rev Gastroenterol Hepatol,2011, 8(9):512-522.
[3] RAZUMILAVA N. and GJ GORES.Cholangiocarcinoma. Lancet, 2014. 383(9935):2168-2179.
[4] NATHNA H, ALOIA TA, VAUTHEY JN, et al.A proposed staging system for intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol, 2009, 16(1):14-22.
[5] ENDO I, GONEN M, YOPP A C, et al.Intrahepatic cholangiocarcinoma:rising frequency, improved survival, and determinants of outcome after resection[J]. Ann Surg, 2008, 248(1):84-96.
[6] CHOI S B, KIM K S, CHOI J Y, et al.The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival[J]. Ann Surg Oncol, 2009, 16(11):3048-3056.
[7] NUZZO G, GIULIANTE F, ARDITO F, et al.Intrahepatic cholangiocarcinoma: prognostic factors after liver resection[J]. Updates Surg, 2010, 62(1):11-19.
[8] USTUNDAG Y, BAYRAKTAR Y.Cholangiocarcinoma: a compact review of the literature[J]. World J Gastroentero, 2008, 14(42):6458-6466.
[9] KHAN S A, DAVIDSON B R, GOLDIN R D, et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update[J]. Gut, 2012, 61(12):1657-1669.
[10] BENSON A R, ABRAMS T A, BEN-JOSEF E, et al.NCCN clinical practice guidelines in oncology:hepatobiliary cancers[J]. J Natl Compr Canc Netw, 2009, 7(4):350-391.
[11] ALVARO D, CANNIZZARO R, LABIANCA R, et al.Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO)[J]. Dig Liver Dis, 2010, 42(12):831-838.
[12] BRIDGEWATER J, GALLE P R, KHAN S A, et al.Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma[J]. J Hepatol, 2014, 60(6):1268-1289.
[13] BENAVIDES M, ANTÓN A, GALLEGO J, et al. Biliary tract cancers: SEOM clinical guidelines[J]. Clin Transl Oncol, 2015, 17(12):982-987.
[14] KUHLMANN J B, BLUM H E.Locoregional therapy for cholangiocarcinoma[J]. Curr Opin Gastroen, 2013, 29(3):324-328.
[15] SLAKEY D P.Radiofrequency ablation of recurrent cholangiocarcinoma[J]. Am Surg, 2002, 68(4):395-397.
[16] MCKINLEY S K, CHAWLA A, FERRONE C R.Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options[J]. Surg Oncol Clin N Am, 2019, 28(4):745-762.
[17] GREEN B L, HOUSE M G.Nonsurgical Approaches to Treat Biliary Tract and Liver Tumors[J]. Surg Oncol Clin N Am, 2019, 28(4):573-586.
[18] KIM J H, WON H J, SHIN Y M, et al.Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma[J]. AJR Am J Roentgenol, 2011,196(2):W205-W209.
[19] FU Y, YANG W, WU W, et al.Radiofrequency ablation in the management of unresectable intrahepatic cholangiocarcinoma[J]. J Vasc Interv Radiol, 2012, 23(5):642-649.
[20] BUTROS S R, SHENOY-BHANGLE A, MUELLER P R, et al.Radiofrequency ablation of intrahepatic cholangiocarcinoma: feasability, local tumor control, and long-term outcome[J]. Clin Imaging, 2014, 38(4):490-494.
[21] WU L, TSILIMIGRAS D I, FAROOQ A, et al.Potential survival benefit of radiofrequency ablation for small solitary intrahepatic cholangiocarcinoma in nonsurgically managed patients: A population-based analysis[J]. J Surg Oncol, 2019, 120(8):1358-1364.
[22] HAN K, KO H K, KIM K W, et al.Radiofrequency ablation in the treatment of unresectable intrahepatic cholangiocarcinoma: systematic review and meta-analysis[J]. J Vasc Interv Radiol, 2015, 26(7):943-948.
[23] Zhang K,Yu J,Yu X,et al.Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma[J].Int J Hyperthermia,2018,34(3):292-297.
[24] Xu C,Li L,Xu W,et al.Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: intermediate-term results[J].Int J Hyperthermia,2019, 36(1):351-358.
[25] 沈颖甜, 朱海东, 陈荔, 等. 肝内胆管细胞癌诊疗研究进展[J]. 介入放射学杂志, 2018, 27(3):285-289.
[26] WRIGHT G P, PERKINS S, JONES H, et al.Surgical Resection Does Not Improve Survival in Multifocal Intrahepatic Cholangiocarcinoma: A Comparison of Surgical Resection with Intra-Arterial Therapies[J]. Ann Surg Oncol, 2018, 25(1):83-90.
[27] MONDACA S, YARMOHAMMADI H, KEMENY N E.Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma[J]. Surg Oncol Clin N Am, 2019, 28(4):717-729.
[28] VENTURINI M, SALLEMI C, AGOSTINI G, et al.Chemoembolization with drug eluting beads preloaded with irinotecan (DEBIRI) vs doxorubicin (DEBDOX) as a second line treatment for liver metastases from cholangiocarcinoma: a preliminary study[J]. Br J Radiol, 2016, 89(1067):20160247.
[29] GOERG F, ZIMMERMANN M, BRUNERS P, et al.Chemoembolization with Degradable Starch Microspheres for Treatment of Patients with Primary or Recurrent Unresectable, Locally Advanced Intrahepatic Cholangiocarcinoma: A Pilot Study[J]. Cardiovasc Intervent Radiol, 2019, 42(12):1709-1717.
[30] KONSTANTINIDIS I T, KOERKAMP B G, DO R K G, et al. Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone[J]. Cancer, 2016, 122(5):758-765.
[31] 李婉慈, 朱晓黎, 王万胜, 等. 中晚期肝内胆管细胞癌介入治疗的临床疗效分析[J]. 介入放射学杂志, 2016, 25(9):813-817.
[32] KIM J H, YOON H K, SUNG K B, et al.Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes[J]. Cancer, 2008, 113(7):1614-1622.
[33] LEE J, YOON W S, KOOM W S, et al.Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review[J]. Strahlenther Onkol, 2019, 195(2):93-102.
[34] GKIKA E, HALLAUER L, KIRSTE S, et al.Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma[J]. BMC Cancer, 2017, 17(1):781.
[35] POLISTINA F A, GUGLIELMI R, BAIOCCHI C, et al.Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience[J]. Radiother Oncol, 2011, 99(2):120-123.
[36] SAXENA A, BESTER L, CHUA T C, et al.Yttrium-90 radiotherapy for unresectable intrahepatic cholangiocarcinoma: a preliminary assessment of this novel treatment option[J]. Ann Surg Oncol, 2010, 17(2):484-491.
[37] HOFFMANN R T, PAPROTTKA P M, SCHON A, et al.Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival[J]. Cardiovasc Intervent Radiol, 2012, 35(1):105-116.